Details of the Drug

General Information of Drug (ID: DMKUE8O)

Drug Name
RP5063
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 2 [1]
Alzheimer disease 8A20 Phase 1 [2]
Attention deficit hyperactivity disorder 6A05.Z Phase 1 [2]
Bipolar disorder 6A60 Phase 1 [2]
Major depressive disorder 6A70.3 Phase 1 [2]
Parkinson disease 8A00.0 Phase 1 [2]
⏷ Show the Full List of Indication(s)
Cross-matching ID
TTD ID
D05XEA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Antagonist [3]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Partial agonist [2]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Partial agonist [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [3]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Partial agonist [2]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Partial agonist [2]
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Partial agonist [2]
Serotoninnorepinephrinedopamine reuptake (SNDR) TT8G3Z7 NOUNIPROTAC Partial agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 1.49E-05 -0.22 -0.58
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271